Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04362189

Enrollment

Registered

2020-04-24

Start date

2020-06-30

Completion date

2021-09-30

Last updated

2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Coronavirus, Stem cells, Mesenchymal stem cells, Adipose-derived mesenchymal stem cells, MSCs, COVID, SARS-CoV-2, Coronavirus disease

Brief summary

Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19. The study purpose is to evaluate the safety and efficacy of four IV infusions of either placebo or HB-adMSCs in subjects with COVID-19.

Detailed description

This is a Phase II, Randomized, Placebo-Controlled, Double-Blinded, Clinical Trial to Assess Efficacy of HB-adMSCs to treat COVID-19 patients. 100 patients will be enrolled. Eligible participants are suspected to have COVID-19 and consent to participate. The primary endpoints of this study are to detect change from baseline in inflammatory markers (IL-6, IL-10, TNF-alpha, C Reactive protein), improving oxygenation, and decreasing time to return to room air (RTRA). In addition, participants will be monitored for overall clinical status by standard clinical laboratories, change from baseline in exploratory markers (D-dimer, myoglobin, troponin, creatinine kinase MB, serum ferritin, CD4:CD8 ratio, CD3-CD56+), time to negative PCR results and clinical improvement according to 7-point ordinal scale, as well as incidence of adverse events.

Interventions

BIOLOGICALHB-adMSC

Hope Biosciences allogeneic adipose-derived mesenchymal stem cells

OTHERPlacebo

Saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Men, and women, over 18 years of age inclusively. 2. Patient is suspected to have COVID-19 infection. 3. Provides consent or consent is given by their legally authorized representative (LAR). 4. Agrees to the collection of venous blood per protocol. 5. Women of childbearing potential (WOCBP) and men (if their sexual partners are WOCBP) must use at least 1 highly effective form of birth control throughout the study and for 6 months after the last dose of study treatment. Highly effective methods of birth control include true sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk, in line with the preferred and usual lifestyle of the patient), surgery (bilateral tubal ligation or occlusion, vasectomized partner), progestogen-only or estrogen/progestogen hormonal contraceptive associated with inhibition of ovulation (oral, patch, injectable, implantable, or intravaginal), intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).

Exclusion criteria

1. Pregnancy, lactation and those who are not pregnant but do not take effective contraceptive measures, in women of childbearing age. Absence of pregnancy will be confirmed through urine pregnancy test. 2. Patients who have participated or are participating in a clinical trial of an experimental vaccine for SARS-CoV-2 or coronavirus during the study or within 30 days. 3. Inability to provide informed consent or to comply with study requirements. 4. Patients with the following concomitant or past medical history: * Both Hypertension and Diabetes Mellitus. * Both Hypertension and Chronic Kidney Disease. * Both Diabetes Mellitus and Chronic Kidney Disease. 5. History or evidence of alcohol abuse. 6. History or evidence of consumption of illicit drugs. 7. Patients requiring mechanical ventilation. 8. Patients who are determined by the Principal Investigator to be unsuitable for study enrollment for other reasons. 9. Any medical disease or condition that, in the opinion of the site Principal Investigator or sub-investigator, precludes study participation. Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial.

Design outcomes

Primary

Measure	Time frame	Description
Return To Room Air (RTRA)	Day 0, 3, 7, and 10	Number of participants who returned to room air
Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 0, 3, 7, and 10	Change from baseline in Tumor Necrosis Factor-Alpha (TNF-alpha) in the blood (pg/mL)
Interleukin-10 (IL-10)	Day 0, 3, 7, and 10	Change from baseline level of Interleukin-10 (IL-10) in the blood (pg/mL)
Interleukin-6 (IL-6)	Day 0, 3, 7, and 10	Change from baseline in Interleukin-6 (IL-6) in the blood (pg/mL)
C-Reactive Protein (CRP)	Day 0, 3, 7, and 10	Change from baseline in C-Reactive Protein (CRP) in the blood (mg/L)
Oxygenation	Day 0, 3, 7, and 10	Change from baseline Oxygenation (%) in the blood

Secondary

Measure	Time frame	Description
CD4+/CD8+ Ratio	Day 0, 3, 7, and 10	Clinical lab evaluation of Ratio of CD4+/CD8+ Cells in the blood
7-Point Ordinal Scale	Day 0, 3, 7, 10, and 28 (End of Study)	Change from baseline in Ordinal scale score. Scale of 1-7. A score of 1 indicates Death and 7 indicates Subject is not Hospitalized and has no Limitations on activities.
Computed Tomography (CT) Score	Day 0 and Day 28	Change from baseline Computed Tomography (CT) Scan Score. A semi-quantitative CT severity scoring was calculated per each of the 5 lobes considering the extent of anatomic involvement: 0, no involvement; 1, \< 5% involvement; 2, 5-25% involvement; 3, 26-50% involvement; 4, 51-75% involvement; and 5, \> 75% involvement. The resulting global CT score was the sum of each individual lobar score and (0 - no involvement to 25 - maximum involvement). Lower score is better.
Chest X-Ray Score	Day 0, Day 28	Change from baseline in Chest X-Ray Score. Scoring was calculated per each of the 5 lobes considering the extent of anatomic involvement: 0, no involvement; 1, \< 5% involvement; 2, 5-25% involvement; 3, 26-50% involvement; 4, 51-75% involvement; and 5, \> 75% involvement. The resulting score was the sum of each individual lobar score and (0 - no involvement to 25 - maximum involvement). Lower score is better.
Glucose	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Glucose in the blood (mg/dL)
Blood Urea Nitrogen (BUN)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Blood Urea Nitrogen (BUN) (mg/dL)
Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Estimated glomerular filtration rate (eGFR) if Non-African American in the blood (mL/min/1.73)
Estimated Glomerular Filtration Rate (eGFR) if African American	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Estimated glomerular filtration rate (eGFR) If African American in the blood (mL/min/1.73)
BUN/Creatinine Ratio	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of BUN/Creatinine Ratio in the blood
Sodium	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Sodium in the blood (mmol/L)
Potassium	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Potassium in the blood (mmol/L)
Chloride	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Chloride in the blood (mmol/L)
Carbon Dioxide Total	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of total level of Carbon Dioxide in the blood (mmol/L)
Calcium	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Calcium in the blood (mg/dL)
Protein Total	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of total level of Protein in the blood (g/dL)
Albumin	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Albumin in the blood (g/dL)
Globulin Total	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of the total level of Globulin in the blood (g/dL)
Albumin/Globulin (A/G) Ratio	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of Albumin/Globulin (A/G) Ratio in the blood
Bilirubin Total	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of the total level of Bilirubin in the blood (mg/dL)
Alkaline Phosphatase	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Alkaline Phosphatase in the blood (IU/L)
Aspartate Aminotransferase (SGOT)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Aspartate aminotransferase (SGOT) in the blood (IU/L)
Alanine Aminotransferase (SGPT)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Alanine aminotransferase (SGPT) in the blood (IU/L)
White Blood Count (WBC)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of count of White Blood Cells (WBCs) in the blood (x10\^3/uL)
Red Blood Cell (RBC) Count	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of Red Blood Cell (RBC) Count in the blood (cells x 10\^3/uL)
Hemoglobin	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Hemoglobin in the blood (g/dL)
Hematocrit	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Hematocrit in the blood (%)
Mean Corpuscular Volume (MCV)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Mean Corpuscular Volume (MCV) in the blood (fL)
Mean Corpuscular Hemoglobin (MCH)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Mean Corpuscular Hemoglobin (MCH) in the blood (pg)
Mean Corpuscular Hemoglobin Concentration (MCHC)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of Mean Corpuscular Hemoglobin Concentration (MCHC) in the blood (g/dL)
Red Cell Distribution Width (RDW)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of Red Cell Distribution Width (RDW) in the blood (%)
Platelets	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Platelets in the blood (cells x10\^3/uL)
Neutrophils	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Neutrophils in the blood (%)
Lymphocytes	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Lymphocytes in the blood (%)
Monocytes	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Monocytes in the blood (%)
Eosinophils	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Eosinophils n the blood (%)
Basophils	Screening, Day 0, 3, 7 and 10	Clinical lab evaluation of level of Basophils in the blood (%)
Absolute Neutrophils	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Absolute Neutrophils in the blood (cells x10\^3/uL)
Absolute Lymphocytes	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Absolute Lymphocytes in the blood (cells x10\^3/uL)
Absolute Monocytes	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Absolute Monocytes in the blood (cells x10\^3/uL)
Absolute Eosinophils	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Absolute Eosinophils in the blood (cells x10\^3/uL)
Absolute Basophils	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Absolute Basophils in the blood (cells x10\^3/uL)
Immature Granulocytes	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Immature Granulocytes in the blood (%)
Absolute Immature Granulocytes	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of level of Absolute Immature Granulocytes in the blood (cells x10\^3/uL)
International Normalized Ratio (INR)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of International Normalized Ratio (INR)
D-dimer	Day 0, 3, 7, and Day 10	Change from baseline in D-dimer in the blood (mg/L)
Partial Thromboplastin Time (PTT)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of Partial Thromboplastin Time (PTT) (seconds)
Prothrombin Time (PT)	Screening, Day 0, 3, 7, and 10	Clinical lab evaluation of Prothrombin Time (seconds)
Myoglobin	Day 0, 3 7, and 10	Clinical lab evaluation of level of Myoglobin in the blood (ng/mL)
Troponin	Day 0, 3, 7, and 10	Clinical lab evaluation of level of Troponin in the blood (ng/mL)
Creatinine Kinase MB (CK-MB)	Day 0, 3, 7, and 10	Clinical lab evaluation of level of Creatinine Kinase (CK-MB) in the blood (ng/mL)
Serum Ferritin	Day 0, 3, 7, and 10	Clinical lab evaluation of level of Serum Ferritin in the blood (ng/mL)
NK Cell Surface Antigen (CD3-CD56+)	Day 0, 3, 7, and 10	Clinical lab evaluation of Percentage of Cells CD3-CD56+ in the blood (%)

Countries

United States

Participant flow

Recruitment details

A total of 59 subjects were assessed for screening, out of which only 48 were enrolled and 11 failed screening. All 48 were randomized in to the two treatment arms: 100MM HB-adMSCs and placebo. 21 out of 48 randomized subjects discontinued.

Pre-assignment details

A total of 59 subjects were assessed for screening, out of which only 48 were enrolled and 11 failed screening.

Participants by arm

Arm	Count
HB-adMSCs Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10. HB-adMSC: Hope Biosciences allogeneic adipose-derived mesenchymal stem cells	33
Placebo Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10. Placebo: Saline	15
Total	48

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Adverse Event	0	2
Overall Study	Death	4	1
Overall Study	Discharge or Transfer to other Hospital	3	0
Overall Study	FDA Clinical Hold	7	2
Overall Study	Lost to Follow-up	0	1
Overall Study	Withdrawal by Subject	1	0

Baseline characteristics

Characteristic	HB-adMSCs	Placebo	Total
Age, Continuous	53.2 Years STANDARD_DEVIATION 17.6	54.7 Years STANDARD_DEVIATION 15.8	53.7 Years STANDARD_DEVIATION 16.9
Body Mass Index (BMI)	30.8 kg/m^2 STANDARD_DEVIATION 6.3	31.2 kg/m^2 STANDARD_DEVIATION 5.9	30.9 kg/m^2 STANDARD_DEVIATION 6.1
Ethnicity (NIH/OMB) Hispanic or Latino	13 Participants	9 Participants	22 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	20 Participants	6 Participants	26 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Height	66.5 in STANDARD_DEVIATION 3.5	66.1 in STANDARD_DEVIATION 4.4	66.4 in STANDARD_DEVIATION 3.7
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	1 Participants	1 Participants	2 Participants
Race (NIH/OMB) Black or African American	11 Participants	3 Participants	14 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	21 Participants	11 Participants	32 Participants
Sex: Female, Male Female	15 Participants	5 Participants	20 Participants
Sex: Female, Male Male	18 Participants	10 Participants	28 Participants
Weight	194.6 lbs STANDARD_DEVIATION 48.2	194.1 lbs STANDARD_DEVIATION 43.7	194.4 lbs STANDARD_DEVIATION 46.3

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	8 / 33	2 / 15
other Total, other adverse events	27 / 33	12 / 15
serious Total, serious adverse events	9 / 33	2 / 15

Outcome results

Primary

C-Reactive Protein (CRP)

Change from baseline in C-Reactive Protein (CRP) in the blood (mg/L)

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	C-Reactive Protein (CRP)	Day 0 (Baseline)	4.9 mg/L	Standard Deviation 5.8
HB-adMSCs	C-Reactive Protein (CRP)	Day 3	4.8 mg/L	Standard Deviation 7.5
HB-adMSCs	C-Reactive Protein (CRP)	Day 7	3.6 mg/L	Standard Deviation 3.4
HB-adMSCs	C-Reactive Protein (CRP)	Day 10	3.5 mg/L	Standard Deviation 4.8
Placebo	C-Reactive Protein (CRP)	Day 10	0.2 mg/L	Standard Deviation 0.2
Placebo	C-Reactive Protein (CRP)	Day 0 (Baseline)	3.8 mg/L	Standard Deviation 5.1
Placebo	C-Reactive Protein (CRP)	Day 7	2.2 mg/L	Standard Deviation 4.1
Placebo	C-Reactive Protein (CRP)	Day 3	4.5 mg/L	Standard Deviation 9.2

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Primary

Interleukin-10 (IL-10)

Change from baseline level of Interleukin-10 (IL-10) in the blood (pg/mL)

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Interleukin-10 (IL-10)	Day 0 (Baseline)	16.3 pg/mL	Standard Deviation 19.4
HB-adMSCs	Interleukin-10 (IL-10)	Day 3	18.8 pg/mL	Standard Deviation 39.1
HB-adMSCs	Interleukin-10 (IL-10)	Day 7	30.8 pg/mL	Standard Deviation 86.3
HB-adMSCs	Interleukin-10 (IL-10)	Day 10	13.0 pg/mL	Standard Deviation 13.5
Placebo	Interleukin-10 (IL-10)	Day 10	8.4 pg/mL	Standard Deviation 10.8
Placebo	Interleukin-10 (IL-10)	Day 0 (Baseline)	11.9 pg/mL	Standard Deviation 16.6
Placebo	Interleukin-10 (IL-10)	Day 7	27.2 pg/mL	Standard Deviation 65.1
Placebo	Interleukin-10 (IL-10)	Day 3	44.7 pg/mL	Standard Deviation 98.9

Primary

Interleukin-6 (IL-6)

Change from baseline in Interleukin-6 (IL-6) in the blood (pg/mL)

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Interleukin-6 (IL-6)	Day 0 (Baseline)	24.3 pg/mL	Standard Deviation 71.8
HB-adMSCs	Interleukin-6 (IL-6)	Day 3	46.3 pg/mL	Standard Deviation 104
HB-adMSCs	Interleukin-6 (IL-6)	Day 7	65.4 pg/mL	Standard Deviation 186.8
HB-adMSCs	Interleukin-6 (IL-6)	Day 10	35.0 pg/mL	Standard Deviation 70.4
Placebo	Interleukin-6 (IL-6)	Day 10	12.4 pg/mL	Standard Deviation 23.9
Placebo	Interleukin-6 (IL-6)	Day 0 (Baseline)	69.4 pg/mL	Standard Deviation 166.5
Placebo	Interleukin-6 (IL-6)	Day 7	197.8 pg/mL	Standard Deviation 539.7
Placebo	Interleukin-6 (IL-6)	Day 3	376.6 pg/mL	Standard Deviation 988.7

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Primary

Oxygenation

Change from baseline Oxygenation (%) in the blood

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Oxygenation	Day 0 (Baseline)	95.3 % of Oxygen Saturation	Standard Deviation 3.1
HB-adMSCs	Oxygenation	Day 7	96.2 % of Oxygen Saturation	Standard Deviation 2.2
HB-adMSCs	Oxygenation	Day 3	95.4 % of Oxygen Saturation	Standard Deviation 3.2
HB-adMSCs	Oxygenation	Day 10	96.7 % of Oxygen Saturation	Standard Deviation 2.5
Placebo	Oxygenation	Day 3	94.5 % of Oxygen Saturation	Standard Deviation 4.7
Placebo	Oxygenation	Day 0 (Baseline)	89.4 % of Oxygen Saturation	Standard Deviation 19.1
Placebo	Oxygenation	Day 10	96.7 % of Oxygen Saturation	Standard Deviation 1.7
Placebo	Oxygenation	Day 7	95.8 % of Oxygen Saturation	Standard Deviation 5.7

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Primary

Return To Room Air (RTRA)

Number of participants who returned to room air

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HB-adMSCs	Return To Room Air (RTRA)	Day 0	15 Participants
HB-adMSCs	Return To Room Air (RTRA)	Day 3	13 Participants
HB-adMSCs	Return To Room Air (RTRA)	Day 7	11 Participants
HB-adMSCs	Return To Room Air (RTRA)	Day 10	12 Participants
Placebo	Return To Room Air (RTRA)	Day 10	8 Participants
Placebo	Return To Room Air (RTRA)	Day 0	4 Participants
Placebo	Return To Room Air (RTRA)	Day 7	7 Participants
Placebo	Return To Room Air (RTRA)	Day 3	8 Participants

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Primary

Tumor Necrosis Factor-Alpha (TNF-alpha)

Change from baseline in Tumor Necrosis Factor-Alpha (TNF-alpha) in the blood (pg/mL)

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 10	20.3 pg/mL	Standard Deviation 11.3
HB-adMSCs	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 3	26.1 pg/mL	Standard Deviation 26.5
HB-adMSCs	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 7	33.4 pg/mL	Standard Deviation 49.8
HB-adMSCs	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 0 (Baseline)	15.5 pg/mL	Standard Deviation 13.9
Placebo	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 10	30.5 pg/mL	Standard Deviation 40.5
Placebo	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 0 (Baseline)	18.2 pg/mL	Standard Deviation 12.3
Placebo	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 3	15.9 pg/mL	Standard Deviation 10
Placebo	Tumor Necrosis Factor-Alpha (TNF-alpha)	Day 7	35.3 pg/mL	Standard Deviation 38.8

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Secondary

7-Point Ordinal Scale

Change from baseline in Ordinal scale score. Scale of 1-7. A score of 1 indicates Death and 7 indicates Subject is not Hospitalized and has no Limitations on activities.

Time frame: Day 0, 3, 7, 10, and 28 (End of Study)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HB-adMSCs	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 28 (End of Study)	9 Participants
HB-adMSCs	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 10	4 Participants
HB-adMSCs	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 0	2 Participants
HB-adMSCs	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 28 (End of Study)	1 Participants
HB-adMSCs	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 0	8 Participants
HB-adMSCs	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 0	6 Participants
HB-adMSCs	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 10	6 Participants
HB-adMSCs	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 3	4 Participants
HB-adMSCs	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 3	3 Participants
HB-adMSCs	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 7	5 Participants
HB-adMSCs	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 3	9 Participants
HB-adMSCs	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 10	2 Participants
HB-adMSCs	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 7	2 Participants
HB-adMSCs	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 28 (End of Study)	0 Participants
HB-adMSCs	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 7	3 Participants
HB-adMSCs	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 0	1 Participants
HB-adMSCs	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 10	1 Participants
HB-adMSCs	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 3	1 Participants
HB-adMSCs	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 7	14 Participants
HB-adMSCs	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 7	0 Participants
HB-adMSCs	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 28 (End of Study)	0 Participants
HB-adMSCs	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 10	2 Participants
HB-adMSCs	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 28 (End of Study)	14 Participants
HB-adMSCs	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or - Day 28 (End of Study)	1 Participants
HB-adMSCs	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 0	15 Participants
HB-adMSCs	7-Point Ordinal Scale	7: Death - Day 0	0 Participants
HB-adMSCs	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 10	12 Participants
HB-adMSCs	7-Point Ordinal Scale	7: Death - Day 3	1 Participants
HB-adMSCs	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 3	12 Participants
HB-adMSCs	7-Point Ordinal Scale	7: Death - Day 7	4 Participants
HB-adMSCs	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 3	3 Participants
HB-adMSCs	7-Point Ordinal Scale	7: Death - Day 10	6 Participants
HB-adMSCs	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 7	5 Participants
HB-adMSCs	7-Point Ordinal Scale	7: Death - Day 28 (End of Study)	8 Participants
HB-adMSCs	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 0	1 Participants
Placebo	7-Point Ordinal Scale	7: Death - Day 28 (End of Study)	2 Participants
Placebo	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 0	1 Participants
Placebo	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 3	3 Participants
Placebo	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 7	5 Participants
Placebo	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 10	5 Participants
Placebo	7-Point Ordinal Scale	1: Not hospitalized, no limitations on activities - Day 28 (End of Study)	7 Participants
Placebo	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 0	4 Participants
Placebo	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 3	5 Participants
Placebo	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 7	7 Participants
Placebo	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 10	7 Participants
Placebo	7-Point Ordinal Scale	2: Not hospitalized, limitation on activities - Day 28 (End of Study)	6 Participants
Placebo	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 0	0 Participants
Placebo	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 3	0 Participants
Placebo	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 7	0 Participants
Placebo	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 10	0 Participants
Placebo	7-Point Ordinal Scale	3: Hospitalized, not requiring supplemental oxygen - Day 28 (End of Study)	0 Participants
Placebo	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 0	8 Participants
Placebo	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 3	6 Participants
Placebo	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 7	1 Participants
Placebo	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 10	0 Participants
Placebo	7-Point Ordinal Scale	4: Hospitalized, requiring supplemental oxygen - Day 28 (End of Study)	0 Participants
Placebo	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 0	2 Participants
Placebo	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 3	1 Participants
Placebo	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 7	1 Participants
Placebo	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 10	2 Participants
Placebo	7-Point Ordinal Scale	5: Hospitalized, on noninvasive ventilation or high flow oxygen devices - Day 28 (End of Study)	0 Participants
Placebo	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 0	0 Participants
Placebo	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 3	0 Participants
Placebo	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 7	1 Participants
Placebo	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or ECMO - Day 10	0 Participants
Placebo	7-Point Ordinal Scale	6: Hospitalized, on invasive mechanical ventilation or - Day 28 (End of Study)	0 Participants
Placebo	7-Point Ordinal Scale	7: Death - Day 0	0 Participants
Placebo	7-Point Ordinal Scale	7: Death - Day 3	0 Participants
Placebo	7-Point Ordinal Scale	7: Death - Day 7	0 Participants
Placebo	7-Point Ordinal Scale	7: Death - Day 10	1 Participants

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Secondary

Absolute Basophils

Clinical lab evaluation of level of Absolute Basophils in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 21 at screening and in Placebo group maximum number analyzed was 10 at screening.These were the largest N for which data for Absolute Basophils was collected

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Absolute Basophils	Day 10	0.0 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Basophils	Screening	0.0 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Basophils	Day 0	0.0 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Basophils	Day 3	0.0 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Basophils	Day 7	0.0 cells x10^3/uL	Standard Deviation 0
Placebo	Absolute Basophils	Screening	0.0 cells x10^3/uL	Standard Deviation 0
Placebo	Absolute Basophils	Day 3	0.0 cells x10^3/uL	Standard Deviation 0
Placebo	Absolute Basophils	Day 0	0.0 cells x10^3/uL	Standard Deviation 0

Secondary

Absolute Eosinophils

Clinical lab evaluation of level of Absolute Eosinophils in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Absolute Eosinophils	Day 10	0.1 cells x10^3/uL	Standard Deviation 0.1
HB-adMSCs	Absolute Eosinophils	Day 3	0.0 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Eosinophils	Day 7	0.0 cells x10^3/uL	Standard Deviation 0.1
HB-adMSCs	Absolute Eosinophils	Screening	0.1 cells x10^3/uL	Standard Deviation 0.3
HB-adMSCs	Absolute Eosinophils	Day 0	0.0 cells x10^3/uL	Standard Deviation 0
Placebo	Absolute Eosinophils	Screening	0.0 cells x10^3/uL	Standard Deviation 0
Placebo	Absolute Eosinophils	Day 3	0.1 cells x10^3/uL	Standard Deviation 0.2
Placebo	Absolute Eosinophils	Day 0	0.0 cells x10^3/uL	Standard Deviation 0

Secondary

Absolute Immature Granulocytes

Clinical lab evaluation of level of Absolute Immature Granulocytes in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 21 at screening and in Placebo group maximum number analyzed was 9 at screening.These were the largest N for which data was collected for Absolute Immature Granulocytes

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Absolute Immature Granulocytes	Day 10	0.0 cells x10^3/uL	Standard Deviation 0.1
HB-adMSCs	Absolute Immature Granulocytes	Day 3	0.2 cells x10^3/uL	Standard Deviation 0.2
HB-adMSCs	Absolute Immature Granulocytes	Day 7	0.1 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Immature Granulocytes	Screening	0.0 cells x10^3/uL	Standard Deviation 0
HB-adMSCs	Absolute Immature Granulocytes	Day 0	0.1 cells x10^3/uL	Standard Deviation 0.2
Placebo	Absolute Immature Granulocytes	Screening	0.1 cells x10^3/uL	Standard Deviation 0.2
Placebo	Absolute Immature Granulocytes	Day 3	0.3 cells x10^3/uL	Standard Deviation 0.5
Placebo	Absolute Immature Granulocytes	Day 0	0.2 cells x10^3/uL	Standard Deviation 0.2

Secondary

Absolute Lymphocytes

Clinical lab evaluation of level of Absolute Lymphocytes in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 21 at screening and in Placebo group maximum number analyzed was 11 at screening. These were the largest N collected for this outcome.

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Absolute Lymphocytes	Screening	1.0 cells x10^3/uL	Standard Deviation 0.6
HB-adMSCs	Absolute Lymphocytes	Day 0	1.0 cells x10^3/uL	Standard Deviation 0.6
HB-adMSCs	Absolute Lymphocytes	Day 3	1.0 cells x10^3/uL	Standard Deviation 0.7
HB-adMSCs	Absolute Lymphocytes	Day 7	0.8 cells x10^3/uL	Standard Deviation 0.3
HB-adMSCs	Absolute Lymphocytes	Day 10	261.1 cells x10^3/uL	Standard Deviation 580.8
Placebo	Absolute Lymphocytes	Screening	1.1 cells x10^3/uL	Standard Deviation 1.1
Placebo	Absolute Lymphocytes	Day 3	1.9 cells x10^3/uL	Standard Deviation 1.4
Placebo	Absolute Lymphocytes	Day 0	1.4 cells x10^3/uL	Standard Deviation 1.1
Placebo	Absolute Lymphocytes	Day 10	2184.0 cells x10^3/uL	—

Secondary

Absolute Monocytes

Clinical lab evaluation of level of Absolute Monocytes in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Absolute Monocytes	Day 10	0.6 cells x10^3/uL	Standard Deviation 0.4
HB-adMSCs	Absolute Monocytes	Day 3	0.7 cells x10^3/uL	Standard Deviation 0.5
HB-adMSCs	Absolute Monocytes	Day 7	0.6 cells x10^3/uL	Standard Deviation 0.6
HB-adMSCs	Absolute Monocytes	Screening	0.4 cells x10^3/uL	Standard Deviation 0.3
HB-adMSCs	Absolute Monocytes	Day 0	1.1 cells x10^3/uL	Standard Deviation 2.5
Placebo	Absolute Monocytes	Screening	0.5 cells x10^3/uL	Standard Deviation 0.4
Placebo	Absolute Monocytes	Day 3	0.8 cells x10^3/uL	Standard Deviation 0.4
Placebo	Absolute Monocytes	Day 0	0.5 cells x10^3/uL	Standard Deviation 0.4

Secondary

Absolute Neutrophils

Clinical lab evaluation of level of Absolute Neutrophils in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 21 at Day screening and in Placebo group maximum number analyzed was 10 at Screening. These were the largest N collected

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Absolute Neutrophils	Day 10	5.3 cells x 10^3/uL	Standard Deviation 4.2
HB-adMSCs	Absolute Neutrophils	Day 3	15.4 cells x 10^3/uL	Standard Deviation 15.6
HB-adMSCs	Absolute Neutrophils	Day 7	7.4 cells x 10^3/uL	Standard Deviation 4.7
HB-adMSCs	Absolute Neutrophils	Screening	7.0 cells x 10^3/uL	Standard Deviation 3.8
HB-adMSCs	Absolute Neutrophils	Day 0	9.7 cells x 10^3/uL	Standard Deviation 10.3
Placebo	Absolute Neutrophils	Screening	7.5 cells x 10^3/uL	Standard Deviation 4.2
Placebo	Absolute Neutrophils	Day 3	13.6 cells x 10^3/uL	Standard Deviation 11.5
Placebo	Absolute Neutrophils	Day 0	7.6 cells x 10^3/uL	Standard Deviation 3.4

Secondary

Alanine Aminotransferase (SGPT)

Clinical lab evaluation of level of Alanine aminotransferase (SGPT) in the blood (IU/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Alanine Aminotransferase (SGPT)	Day 0	38.5 IU/L	Standard Deviation 39.7
HB-adMSCs	Alanine Aminotransferase (SGPT)	Day 7	46.4 IU/L	Standard Deviation 39.7
HB-adMSCs	Alanine Aminotransferase (SGPT)	Screening	50.8 IU/L	Standard Deviation 58.3
HB-adMSCs	Alanine Aminotransferase (SGPT)	Day 10	42.2 IU/L	Standard Deviation 29.3
HB-adMSCs	Alanine Aminotransferase (SGPT)	Day 3	68.0 IU/L	Standard Deviation 78.8
Placebo	Alanine Aminotransferase (SGPT)	Day 10	70.8 IU/L	Standard Deviation 83.4
Placebo	Alanine Aminotransferase (SGPT)	Day 0	57.2 IU/L	Standard Deviation 38.6
Placebo	Alanine Aminotransferase (SGPT)	Day 3	107.0 IU/L	Standard Deviation 122.3
Placebo	Alanine Aminotransferase (SGPT)	Day 7	108.7 IU/L	Standard Deviation 106.2
Placebo	Alanine Aminotransferase (SGPT)	Screening	77.0 IU/L	Standard Deviation 124.5

Secondary

Albumin

Clinical lab evaluation of level of Albumin in the blood (g/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Albumin	Day 0	3.4 g/dL	Standard Deviation 0.5
HB-adMSCs	Albumin	Day 7	3.2 g/dL	Standard Deviation 0.8
HB-adMSCs	Albumin	Day 3	3.2 g/dL	Standard Deviation 0.7
HB-adMSCs	Albumin	Day 10	3.4 g/dL	Standard Deviation 0.8
HB-adMSCs	Albumin	Screening	3.4 g/dL	Standard Deviation 0.5
Placebo	Albumin	Day 10	3.9 g/dL	Standard Deviation 0.4
Placebo	Albumin	Screening	3.6 g/dL	Standard Deviation 0.6
Placebo	Albumin	Day 0	3.5 g/dL	Standard Deviation 0.6
Placebo	Albumin	Day 3	3.4 g/dL	Standard Deviation 0.6
Placebo	Albumin	Day 7	3.5 g/dL	Standard Deviation 0.8

Secondary

Albumin/Globulin (A/G) Ratio

Clinical lab evaluation of Albumin/Globulin (A/G) Ratio in the blood

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 14 (at Day 7) and in Placebo group maximum number analyzed was 8 at (Day 10). These were the largest N collected.

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Albumin/Globulin (A/G) Ratio	Day 3	1.5 Ratio	Standard Deviation 0.4
HB-adMSCs	Albumin/Globulin (A/G) Ratio	Day 0	1.4 Ratio	Standard Deviation 0.3
HB-adMSCs	Albumin/Globulin (A/G) Ratio	Day 7	1.4 Ratio	Standard Deviation 0.3
HB-adMSCs	Albumin/Globulin (A/G) Ratio	Day 10	1.3 Ratio	Standard Deviation 0.4
Placebo	Albumin/Globulin (A/G) Ratio	Day 10	1.7 Ratio	Standard Deviation 0.4
Placebo	Albumin/Globulin (A/G) Ratio	Day 0	1.3 Ratio	Standard Deviation 0.3
Placebo	Albumin/Globulin (A/G) Ratio	Day 3	1.5 Ratio	Standard Deviation 0.4
Placebo	Albumin/Globulin (A/G) Ratio	Day 7	1.4 Ratio	Standard Deviation 0.4
Unknown	Albumin/Globulin (A/G) Ratio	Screening	— Ratio	—

Secondary

Alkaline Phosphatase

Clinical lab evaluation of level of Alkaline Phosphatase in the blood (IU/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Alkaline Phosphatase	Day 0	84.9 IU/L	Standard Deviation 35.3
HB-adMSCs	Alkaline Phosphatase	Day 7	83.9 IU/L	Standard Deviation 35
HB-adMSCs	Alkaline Phosphatase	Day 3	101.8 IU/L	Standard Deviation 71.1
HB-adMSCs	Alkaline Phosphatase	Day 10	94.2 IU/L	Standard Deviation 47.3
HB-adMSCs	Alkaline Phosphatase	Screening	85.5 IU/L	Standard Deviation 37.2
Placebo	Alkaline Phosphatase	Day 10	79.1 IU/L	Standard Deviation 19.3
Placebo	Alkaline Phosphatase	Screening	71.9 IU/L	Standard Deviation 19.8
Placebo	Alkaline Phosphatase	Day 0	66.5 IU/L	Standard Deviation 21.6
Placebo	Alkaline Phosphatase	Day 3	67.7 IU/L	Standard Deviation 22.1
Placebo	Alkaline Phosphatase	Day 7	86.6 IU/L	Standard Deviation 15.2

Secondary

Aspartate Aminotransferase (SGOT)

Clinical lab evaluation of level of Aspartate aminotransferase (SGOT) in the blood (IU/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Aspartate Aminotransferase (SGOT)	Day 7	41.4 IU/L	Standard Deviation 52.7
HB-adMSCs	Aspartate Aminotransferase (SGOT)	Screening	41.9 IU/L	Standard Deviation 33.3
HB-adMSCs	Aspartate Aminotransferase (SGOT)	Day 3	69.7 IU/L	Standard Deviation 117.3
HB-adMSCs	Aspartate Aminotransferase (SGOT)	Day 10	36.6 IU/L	Standard Deviation 20
HB-adMSCs	Aspartate Aminotransferase (SGOT)	Day 0	30.0 IU/L	Standard Deviation 18.3
Placebo	Aspartate Aminotransferase (SGOT)	Day 10	27.6 IU/L	Standard Deviation 10.1
Placebo	Aspartate Aminotransferase (SGOT)	Day 0	38.2 IU/L	Standard Deviation 26.4
Placebo	Aspartate Aminotransferase (SGOT)	Day 3	47.3 IU/L	Standard Deviation 33.9
Placebo	Aspartate Aminotransferase (SGOT)	Day 7	46.1 IU/L	Standard Deviation 32.8
Placebo	Aspartate Aminotransferase (SGOT)	Screening	41.1 IU/L	Standard Deviation 28.2

Secondary

Basophils

Clinical lab evaluation of level of Basophils in the blood (%)

Time frame: Screening, Day 0, 3, 7 and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Basophils	Day 0	0.1 % of Basophils	Standard Deviation 0.4
HB-adMSCs	Basophils	Day 7	0.4 % of Basophils	Standard Deviation 0.7
HB-adMSCs	Basophils	Day 3	0.2 % of Basophils	Standard Deviation 0.3
HB-adMSCs	Basophils	Day 10	0.4 % of Basophils	Standard Deviation 0.9
HB-adMSCs	Basophils	Screening	0.3 % of Basophils	Standard Deviation 0.4
Placebo	Basophils	Day 10	0.2 % of Basophils	Standard Deviation 0.3
Placebo	Basophils	Screening	0.1 % of Basophils	Standard Deviation 0.2
Placebo	Basophils	Day 0	0.1 % of Basophils	Standard Deviation 0.3
Placebo	Basophils	Day 3	0.0 % of Basophils	Standard Deviation 0
Placebo	Basophils	Day 7	0.8 % of Basophils	Standard Deviation 0.9

Secondary

Bilirubin Total

Clinical lab evaluation of the total level of Bilirubin in the blood (mg/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Bilirubin Total	Day 3	0.7 mg/dL	Standard Deviation 0.8
HB-adMSCs	Bilirubin Total	Day 7	0.5 mg/dL	Standard Deviation 0.2
HB-adMSCs	Bilirubin Total	Day 10	0.5 mg/dL	Standard Deviation 0.2
HB-adMSCs	Bilirubin Total	Screening	0.6 mg/dL	Standard Deviation 0.4
HB-adMSCs	Bilirubin Total	Day 0	0.4 mg/dL	Standard Deviation 0.2
Placebo	Bilirubin Total	Day 0	0.4 mg/dL	Standard Deviation 0.3
Placebo	Bilirubin Total	Screening	0.5 mg/dL	Standard Deviation 0.2
Placebo	Bilirubin Total	Day 7	0.5 mg/dL	Standard Deviation 0.4
Placebo	Bilirubin Total	Day 3	0.4 mg/dL	Standard Deviation 0.2
Placebo	Bilirubin Total	Day 10	0.6 mg/dL	Standard Deviation 0.5

Secondary

Blood Urea Nitrogen (BUN)

Clinical lab evaluation of level of Blood Urea Nitrogen (BUN) (mg/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Blood Urea Nitrogen (BUN)	Day 0	22.9 mg/dL	Standard Deviation 17.4
HB-adMSCs	Blood Urea Nitrogen (BUN)	Day 7	28.4 mg/dL	Standard Deviation 28.1
HB-adMSCs	Blood Urea Nitrogen (BUN)	Day 3	24.0 mg/dL	Standard Deviation 18.5
HB-adMSCs	Blood Urea Nitrogen (BUN)	Day 10	19.8 mg/dL	Standard Deviation 12.1
HB-adMSCs	Blood Urea Nitrogen (BUN)	Screening	19.7 mg/dL	Standard Deviation 14.3
Placebo	Blood Urea Nitrogen (BUN)	Day 10	14.9 mg/dL	Standard Deviation 6
Placebo	Blood Urea Nitrogen (BUN)	Screening	14.3 mg/dL	Standard Deviation 5.8
Placebo	Blood Urea Nitrogen (BUN)	Day 0	15.6 mg/dL	Standard Deviation 4.8
Placebo	Blood Urea Nitrogen (BUN)	Day 3	12.7 mg/dL	Standard Deviation 4.4
Placebo	Blood Urea Nitrogen (BUN)	Day 7	19.9 mg/dL	Standard Deviation 7.8

Secondary

BUN/Creatinine Ratio

Clinical lab evaluation of BUN/Creatinine Ratio in the blood

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	BUN/Creatinine Ratio	Day 0	22.9 Ratio	Standard Deviation 11
HB-adMSCs	BUN/Creatinine Ratio	Day 7	30.3 Ratio	Standard Deviation 24.6
HB-adMSCs	BUN/Creatinine Ratio	Day 3	22.4 Ratio	Standard Deviation 6.9
HB-adMSCs	BUN/Creatinine Ratio	Day 10	20.2 Ratio	Standard Deviation 7.9
HB-adMSCs	BUN/Creatinine Ratio	Screening	18.1 Ratio	Standard Deviation 6.6
Placebo	BUN/Creatinine Ratio	Day 10	18.4 Ratio	Standard Deviation 7.6
Placebo	BUN/Creatinine Ratio	Screening	18.9 Ratio	Standard Deviation 2.7
Placebo	BUN/Creatinine Ratio	Day 0	20.7 Ratio	Standard Deviation 4.7
Placebo	BUN/Creatinine Ratio	Day 3	19.2 Ratio	Standard Deviation 5.8
Placebo	BUN/Creatinine Ratio	Day 7	26.1 Ratio	Standard Deviation 8

Secondary

Calcium

Clinical lab evaluation of level of Calcium in the blood (mg/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Calcium	Day 0	8.4 mg/dL	Standard Deviation 0.5
HB-adMSCs	Calcium	Day 7	8.4 mg/dL	Standard Deviation 1.1
HB-adMSCs	Calcium	Day 3	8.3 mg/dL	Standard Deviation 0.7
HB-adMSCs	Calcium	Day 10	8.6 mg/dL	Standard Deviation 1.1
HB-adMSCs	Calcium	Screening	8.6 mg/dL	Standard Deviation 0.5
Placebo	Calcium	Day 10	9.1 mg/dL	Standard Deviation 0.4
Placebo	Calcium	Screening	8.7 mg/dL	Standard Deviation 0.6
Placebo	Calcium	Day 0	8.3 mg/dL	Standard Deviation 0.7
Placebo	Calcium	Day 3	8.3 mg/dL	Standard Deviation 0.8
Placebo	Calcium	Day 7	8.7 mg/dL	Standard Deviation 0.9

Secondary

Carbon Dioxide Total

Clinical lab evaluation of total level of Carbon Dioxide in the blood (mmol/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Carbon Dioxide Total	Day 7	23.8 mmol/L	Standard Deviation 3.5
HB-adMSCs	Carbon Dioxide Total	Screening	25.2 mmol/L	Standard Deviation 4.5
HB-adMSCs	Carbon Dioxide Total	Day 0	24.1 mmol/L	Standard Deviation 4.8
HB-adMSCs	Carbon Dioxide Total	Day 3	24.6 mmol/L	Standard Deviation 4
HB-adMSCs	Carbon Dioxide Total	Day 10	21.9 mmol/L	Standard Deviation 3.8
Placebo	Carbon Dioxide Total	Day 3	25.3 mmol/L	Standard Deviation 2.8
Placebo	Carbon Dioxide Total	Day 10	25.4 mmol/L	Standard Deviation 3.1
Placebo	Carbon Dioxide Total	Day 7	26.3 mmol/L	Standard Deviation 2.8
Placebo	Carbon Dioxide Total	Day 0	25.3 mmol/L	Standard Deviation 4.4
Placebo	Carbon Dioxide Total	Screening	25.4 mmol/L	Standard Deviation 3.1

Secondary

CD4+/CD8+ Ratio

Clinical lab evaluation of Ratio of CD4+/CD8+ Cells in the blood

Time frame: Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	CD4+/CD8+ Ratio	Day 0	2.5 Ratio	Standard Deviation 1.7
HB-adMSCs	CD4+/CD8+ Ratio	Day 7	2.4 Ratio	Standard Deviation 1.4
HB-adMSCs	CD4+/CD8+ Ratio	Day 3	2.5 Ratio	Standard Deviation 1.3
HB-adMSCs	CD4+/CD8+ Ratio	Day 10	2.4 Ratio	Standard Deviation 0.9
Placebo	CD4+/CD8+ Ratio	Day 10	2.3 Ratio	Standard Deviation 1.3
Placebo	CD4+/CD8+ Ratio	Day 0	1.9 Ratio	Standard Deviation 0.9
Placebo	CD4+/CD8+ Ratio	Day 3	2.6 Ratio	Standard Deviation 1.7
Placebo	CD4+/CD8+ Ratio	Day 7	2.4 Ratio	Standard Deviation 1.4

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Secondary

Chest X-Ray Score

Change from baseline in Chest X-Ray Score. Scoring was calculated per each of the 5 lobes considering the extent of anatomic involvement: 0, no involvement; 1, \< 5% involvement; 2, 5-25% involvement; 3, 26-50% involvement; 4, 51-75% involvement; and 5, \> 75% involvement. The resulting score was the sum of each individual lobar score and (0 - no involvement to 25 - maximum involvement). Lower score is better.

Time frame: Day 0, Day 28

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Chest X-Ray Score	Day 0	2.9 Score on a Scale 0-25	Standard Deviation 1.6
HB-adMSCs	Chest X-Ray Score	Day 28	1.7 Score on a Scale 0-25	Standard Deviation 1.6
Placebo	Chest X-Ray Score	Day 0	2.7 Score on a Scale 0-25	Standard Deviation 0.6
Placebo	Chest X-Ray Score	Day 28	1.5 Score on a Scale 0-25	Standard Deviation 2.1

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Secondary

Chloride

Clinical lab evaluation of level of Chloride in the blood (mmol/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Chloride	Day 0	103.3 mmol/L	Standard Deviation 3.7
HB-adMSCs	Chloride	Day 7	102.5 mmol/L	Standard Deviation 5.5
HB-adMSCs	Chloride	Day 3	103.3 mmol/L	Standard Deviation 4.2
HB-adMSCs	Chloride	Day 10	101.9 mmol/L	Standard Deviation 4.6
HB-adMSCs	Chloride	Screening	103.0 mmol/L	Standard Deviation 3.9
Placebo	Chloride	Day 10	104.1 mmol/L	Standard Deviation 1.4
Placebo	Chloride	Screening	102.2 mmol/L	Standard Deviation 2.9
Placebo	Chloride	Day 0	101.0 mmol/L	Standard Deviation 4.4
Placebo	Chloride	Day 3	101.8 mmol/L	Standard Deviation 4.1
Placebo	Chloride	Day 7	102.1 mmol/L	Standard Deviation 2.1

Secondary

Computed Tomography (CT) Score

Change from baseline Computed Tomography (CT) Scan Score. A semi-quantitative CT severity scoring was calculated per each of the 5 lobes considering the extent of anatomic involvement: 0, no involvement; 1, \< 5% involvement; 2, 5-25% involvement; 3, 26-50% involvement; 4, 51-75% involvement; and 5, \> 75% involvement. The resulting global CT score was the sum of each individual lobar score and (0 - no involvement to 25 - maximum involvement). Lower score is better.

Time frame: Day 0 and Day 28

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Computed Tomography (CT) Score	Day 0	2.9 Score on a Scale 0-25	Standard Deviation 1.4
HB-adMSCs	Computed Tomography (CT) Score	Day 28	1.2 Score on a Scale 0-25	Standard Deviation 1.6
Placebo	Computed Tomography (CT) Score	Day 0	3.0 Score on a Scale 0-25	Standard Deviation 0.9
Placebo	Computed Tomography (CT) Score	Day 28	1.2 Score on a Scale 0-25	Standard Deviation 1.2

Comparison: Analyses relied on Bayesian inference for test of superiority via generalized linear mixed model.

Secondary

Creatinine Kinase MB (CK-MB)

Clinical lab evaluation of level of Creatinine Kinase (CK-MB) in the blood (ng/mL)

Time frame: Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 19 at Day 0 and in Placebo group maximum number analyzed was 8 at Day 0.

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Creatinine Kinase MB (CK-MB)	Day 0	2.6 ng/mL	Standard Deviation 2.6
HB-adMSCs	Creatinine Kinase MB (CK-MB)	Day 3	3.0 ng/mL	Standard Deviation 4.6
HB-adMSCs	Creatinine Kinase MB (CK-MB)	Day 7	3.3 ng/mL	Standard Deviation 2.9
HB-adMSCs	Creatinine Kinase MB (CK-MB)	Day 10	3.7 ng/mL	Standard Deviation 3.9
Placebo	Creatinine Kinase MB (CK-MB)	Day 10	1.9 ng/mL	—
Placebo	Creatinine Kinase MB (CK-MB)	Day 0	2.0 ng/mL	Standard Deviation 1.1
Placebo	Creatinine Kinase MB (CK-MB)	Day 7	2.3 ng/mL	Standard Deviation 1.4
Placebo	Creatinine Kinase MB (CK-MB)	Day 3	2.2 ng/mL	Standard Deviation 1.2

Secondary

D-dimer

Change from baseline in D-dimer in the blood (mg/L)

Time frame: Day 0, 3, 7, and Day 10

Population: We had 24 participants in the treatment group and 9 in the placebo who had D-dimer values available.

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	D-dimer	Day 7	0.7 mg/L	Standard Deviation 0.5
HB-adMSCs	D-dimer	Day 3	1.2 mg/L	Standard Deviation 1.7
HB-adMSCs	D-dimer	Day 10	6.8 mg/L	Standard Deviation 7.7
HB-adMSCs	D-dimer	Day 0	1.3 mg/L	Standard Deviation 1.4
Placebo	D-dimer	Day 3	2.3 mg/L	Standard Deviation 2.8
Placebo	D-dimer	Day 0	2.1 mg/L	Standard Deviation 2.6
Placebo	D-dimer	Day 7	13.6 mg/L	Standard Deviation 9.1

Secondary

Eosinophils

Clinical lab evaluation of level of Eosinophils n the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Eosinophils	Day 3	0.2 % of Eosinophils	Standard Deviation 0.6
HB-adMSCs	Eosinophils	Day 0	0.2 % of Eosinophils	Standard Deviation 0.5
HB-adMSCs	Eosinophils	Day 7	2.5 % of Eosinophils	Standard Deviation 9.2
HB-adMSCs	Eosinophils	Day 10	1.1 % of Eosinophils	Standard Deviation 1.4
HB-adMSCs	Eosinophils	Screening	1.1 % of Eosinophils	Standard Deviation 3.1
Placebo	Eosinophils	Day 10	1.0 % of Eosinophils	Standard Deviation 1.1
Placebo	Eosinophils	Screening	0.1 % of Eosinophils	Standard Deviation 0.5
Placebo	Eosinophils	Day 0	0.3 % of Eosinophils	Standard Deviation 0.5
Placebo	Eosinophils	Day 3	0.8 % of Eosinophils	Standard Deviation 1.4
Placebo	Eosinophils	Day 7	0.7 % of Eosinophils	Standard Deviation 1

Secondary

Estimated Glomerular Filtration Rate (eGFR) if African American

Clinical lab evaluation of level of Estimated glomerular filtration rate (eGFR) If African American in the blood (mL/min/1.73)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 7 at Day 0 and in Placebo group maximum number analyzed was 2 at Day 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 7	78.8 mL/min/1.73	Standard Deviation 50.1
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 3	98.2 mL/min/1.73	Standard Deviation 58.9
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 10	78.4 mL/min/1.73	Standard Deviation 45.7
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if African American	Screening	106.4 mL/min/1.73	Standard Deviation 37.3
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 0	74.3 mL/min/1.73	Standard Deviation 42.7
Placebo	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 10	94.5 mL/min/1.73	Standard Deviation 26.2
Placebo	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 0	107.0 mL/min/1.73	—
Placebo	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 3	97.0 mL/min/1.73	—
Placebo	Estimated Glomerular Filtration Rate (eGFR) if African American	Day 7	107.0 mL/min/1.73	—

Secondary

Estimated Glomerular Filtration Rate (eGFR) if Non-African American

Clinical lab evaluation of level of Estimated glomerular filtration rate (eGFR) if Non-African American in the blood (mL/min/1.73)

Time frame: Screening, Day 0, 3, 7, and 10

Population: Estimated glomerular filtration rate (eGFR) if Non-African American

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 3	113.4 mL/min/1.73	Standard Deviation 25.2
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 7	102.8 mL/min/1.73	Standard Deviation 44.8
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 10	107.0 mL/min/1.73	Standard Deviation 36
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Screening	230.3 mL/min/1.73	Standard Deviation 270.1
HB-adMSCs	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 0	143.0 mL/min/1.73	Standard Deviation 103.8
Placebo	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 0	117.0 mL/min/1.73	Standard Deviation 33.9
Placebo	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Screening	127.1 mL/min/1.73	Standard Deviation 30.7
Placebo	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 7	109.6 mL/min/1.73	Standard Deviation 16.5
Placebo	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 3	112.8 mL/min/1.73	Standard Deviation 22.4
Placebo	Estimated Glomerular Filtration Rate (eGFR) if Non-African American	Day 10	108.0 mL/min/1.73	Standard Deviation 18

Secondary

Globulin Total

Clinical lab evaluation of the total level of Globulin in the blood (g/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Globulin Total	Day 0	2.6 g/dL	Standard Deviation 0.5
HB-adMSCs	Globulin Total	Day 7	2.5 g/dL	Standard Deviation 0.5
HB-adMSCs	Globulin Total	Day 3	2.5 g/dL	Standard Deviation 0.5
HB-adMSCs	Globulin Total	Day 10	2.6 g/dL	Standard Deviation 0.6
HB-adMSCs	Globulin Total	Screening	2.8 g/dL	Standard Deviation 0.6
Placebo	Globulin Total	Day 10	2.3 g/dL	Standard Deviation 0.4
Placebo	Globulin Total	Screening	2.9 g/dL	Standard Deviation 0.5
Placebo	Globulin Total	Day 0	2.6 g/dL	Standard Deviation 0.4
Placebo	Globulin Total	Day 3	2.6 g/dL	Standard Deviation 0.5
Placebo	Globulin Total	Day 7	2.6 g/dL	Standard Deviation 0.4

Secondary

Glucose

Clinical lab evaluation of level of Glucose in the blood (mg/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Glucose	Day 0	153.4 mg/dL	Standard Deviation 89
HB-adMSCs	Glucose	Day 7	175.7 mg/dL	Standard Deviation 106.4
HB-adMSCs	Glucose	Day 3	148.2 mg/dL	Standard Deviation 74.8
HB-adMSCs	Glucose	Day 10	166.9 mg/dL	Standard Deviation 110
HB-adMSCs	Glucose	Screening	139.3 mg/dL	Standard Deviation 58
Placebo	Glucose	Day 10	129.8 mg/dL	Standard Deviation 74.4
Placebo	Glucose	Screening	148.1 mg/dL	Standard Deviation 55.4
Placebo	Glucose	Day 0	165.4 mg/dL	Standard Deviation 52.5
Placebo	Glucose	Day 3	145.6 mg/dL	Standard Deviation 58.7
Placebo	Glucose	Day 7	165.7 mg/dL	Standard Deviation 37.5

Secondary

Hematocrit

Clinical lab evaluation of level of Hematocrit in the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Hematocrit	Day 0	37.3 % of RBCs	Standard Deviation 6.8
HB-adMSCs	Hematocrit	Day 7	33.2 % of RBCs	Standard Deviation 6.3
HB-adMSCs	Hematocrit	Day 3	36.0 % of RBCs	Standard Deviation 7.7
HB-adMSCs	Hematocrit	Day 10	34.6 % of RBCs	Standard Deviation 8.3
HB-adMSCs	Hematocrit	Screening	37.3 % of RBCs	Standard Deviation 6.7
Placebo	Hematocrit	Day 10	36.7 % of RBCs	Standard Deviation 4.5
Placebo	Hematocrit	Screening	39.5 % of RBCs	Standard Deviation 6.3
Placebo	Hematocrit	Day 0	38.8 % of RBCs	Standard Deviation 8.7
Placebo	Hematocrit	Day 3	38.0 % of RBCs	Standard Deviation 6.3
Placebo	Hematocrit	Day 7	39.6 % of RBCs	Standard Deviation 7.8

Secondary

Hemoglobin

Clinical lab evaluation of level of Hemoglobin in the blood (g/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Hemoglobin	Day 0	11.9 g/dL	Standard Deviation 2.5
HB-adMSCs	Hemoglobin	Day 7	10.8 g/dL	Standard Deviation 2.2
HB-adMSCs	Hemoglobin	Day 3	11.6 g/dL	Standard Deviation 2.7
HB-adMSCs	Hemoglobin	Day 10	11.1 g/dL	Standard Deviation 2.8
HB-adMSCs	Hemoglobin	Screening	12.0 g/dL	Standard Deviation 2.5
Placebo	Hemoglobin	Day 10	12.4 g/dL	Standard Deviation 1.7
Placebo	Hemoglobin	Screening	12.8 g/dL	Standard Deviation 2.3
Placebo	Hemoglobin	Day 0	12.5 g/dL	Standard Deviation 3.1
Placebo	Hemoglobin	Day 3	12.1 g/dL	Standard Deviation 2
Placebo	Hemoglobin	Day 7	13.4 g/dL	Standard Deviation 2.8

Secondary

Immature Granulocytes

Clinical lab evaluation of level of Immature Granulocytes in the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 21 at screening and in Placebo group maximum number analyzed was 9 at screening. These were the largest N for which data for was collected for Immature granulocytes

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Immature Granulocytes	Day 10	0.6 % of Immature Granulocytes	Standard Deviation 0.5
HB-adMSCs	Immature Granulocytes	Day 3	1.6 % of Immature Granulocytes	Standard Deviation 1.7
HB-adMSCs	Immature Granulocytes	Day 7	1.0 % of Immature Granulocytes	Standard Deviation 0.8
HB-adMSCs	Immature Granulocytes	Screening	0.4 % of Immature Granulocytes	Standard Deviation 0.6
HB-adMSCs	Immature Granulocytes	Day 0	1.0 % of Immature Granulocytes	Standard Deviation 1.1
Placebo	Immature Granulocytes	Screening	1.2 % of Immature Granulocytes	Standard Deviation 1.1
Placebo	Immature Granulocytes	Day 3	1.4 % of Immature Granulocytes	Standard Deviation 1.1
Placebo	Immature Granulocytes	Day 0	1.8 % of Immature Granulocytes	Standard Deviation 1.5

Secondary

International Normalized Ratio (INR)

Clinical lab evaluation of International Normalized Ratio (INR)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	International Normalized Ratio (INR)	Day 7	1.2 Ratio	Standard Deviation 0.4
HB-adMSCs	International Normalized Ratio (INR)	Day 0	1.2 Ratio	Standard Deviation 0.3
HB-adMSCs	International Normalized Ratio (INR)	Screening	1.1 Ratio	Standard Deviation 0.1
HB-adMSCs	International Normalized Ratio (INR)	Day 10	1.4 Ratio	Standard Deviation 0.6
HB-adMSCs	International Normalized Ratio (INR)	Day 3	1.2 Ratio	Standard Deviation 0.3
Placebo	International Normalized Ratio (INR)	Day 10	1.1 Ratio	Standard Deviation 0.2
Placebo	International Normalized Ratio (INR)	Day 3	1.1 Ratio	Standard Deviation 0.1
Placebo	International Normalized Ratio (INR)	Day 7	1.1 Ratio	Standard Deviation 0.1
Placebo	International Normalized Ratio (INR)	Screening	1.1 Ratio	Standard Deviation 0.1
Placebo	International Normalized Ratio (INR)	Day 0	1.1 Ratio	Standard Deviation 0.1

Secondary

Lymphocytes

Clinical lab evaluation of level of Lymphocytes in the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Lymphocytes	Day 0	11.3 Percentage of Lymphocytes (%)	Standard Deviation 8.2
HB-adMSCs	Lymphocytes	Day 7	17.4 Percentage of Lymphocytes (%)	Standard Deviation 13.3
HB-adMSCs	Lymphocytes	Day 3	14.5 Percentage of Lymphocytes (%)	Standard Deviation 13.9
HB-adMSCs	Lymphocytes	Day 10	17.0 Percentage of Lymphocytes (%)	Standard Deviation 11.8
HB-adMSCs	Lymphocytes	Screening	14.4 Percentage of Lymphocytes (%)	Standard Deviation 11.4
Placebo	Lymphocytes	Day 10	25.7 Percentage of Lymphocytes (%)	Standard Deviation 14.2
Placebo	Lymphocytes	Screening	16.0 Percentage of Lymphocytes (%)	Standard Deviation 11.1
Placebo	Lymphocytes	Day 0	12.1 Percentage of Lymphocytes (%)	Standard Deviation 7.9
Placebo	Lymphocytes	Day 3	17.2 Percentage of Lymphocytes (%)	Standard Deviation 12.7
Placebo	Lymphocytes	Day 7	16.8 Percentage of Lymphocytes (%)	Standard Deviation 13.5

Secondary

Mean Corpuscular Hemoglobin Concentration (MCHC)

Clinical lab evaluation of Mean Corpuscular Hemoglobin Concentration (MCHC) in the blood (g/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 0	31.9 g/dL	Standard Deviation 2
HB-adMSCs	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 7	32.6 g/dL	Standard Deviation 2.1
HB-adMSCs	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 3	32.1 g/dL	Standard Deviation 1.9
HB-adMSCs	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 10	31.9 g/dL	Standard Deviation 2
HB-adMSCs	Mean Corpuscular Hemoglobin Concentration (MCHC)	Screening	32.0 g/dL	Standard Deviation 1.8
Placebo	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 10	33.7 g/dL	Standard Deviation 0.8
Placebo	Mean Corpuscular Hemoglobin Concentration (MCHC)	Screening	32.3 g/dL	Standard Deviation 1.6
Placebo	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 0	32.0 g/dL	Standard Deviation 1.8
Placebo	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 3	31.8 g/dL	Standard Deviation 1.9
Placebo	Mean Corpuscular Hemoglobin Concentration (MCHC)	Day 7	33.6 g/dL	Standard Deviation 1.2

Secondary

Mean Corpuscular Hemoglobin (MCH)

Clinical lab evaluation of level of Mean Corpuscular Hemoglobin (MCH) in the blood (pg)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Mean Corpuscular Hemoglobin (MCH)	Day 0	28.6 pg	Standard Deviation 3.8
HB-adMSCs	Mean Corpuscular Hemoglobin (MCH)	Day 7	28.3 pg	Standard Deviation 3.9
HB-adMSCs	Mean Corpuscular Hemoglobin (MCH)	Day 3	28.8 pg	Standard Deviation 3.9
HB-adMSCs	Mean Corpuscular Hemoglobin (MCH)	Day 10	28.7 pg	Standard Deviation 3.1
HB-adMSCs	Mean Corpuscular Hemoglobin (MCH)	Screening	28.5 pg	Standard Deviation 3.9
Placebo	Mean Corpuscular Hemoglobin (MCH)	Day 10	28.7 pg	Standard Deviation 1
Placebo	Mean Corpuscular Hemoglobin (MCH)	Screening	45.4 pg	Standard Deviation 67.6
Placebo	Mean Corpuscular Hemoglobin (MCH)	Day 0	27.8 pg	Standard Deviation 2.5
Placebo	Mean Corpuscular Hemoglobin (MCH)	Day 3	27.4 pg	Standard Deviation 2.9
Placebo	Mean Corpuscular Hemoglobin (MCH)	Day 7	28.7 pg	Standard Deviation 1.5

Secondary

Mean Corpuscular Volume (MCV)

Clinical lab evaluation of level of Mean Corpuscular Volume (MCV) in the blood (fL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Mean Corpuscular Volume (MCV)	Day 7	86.8 fL	Standard Deviation 9.5
HB-adMSCs	Mean Corpuscular Volume (MCV)	Day 10	89.8 fL	Standard Deviation 8.7
HB-adMSCs	Mean Corpuscular Volume (MCV)	Screening	88.8 fL	Standard Deviation 9.7
HB-adMSCs	Mean Corpuscular Volume (MCV)	Day 0	89.6 fL	Standard Deviation 8.9
HB-adMSCs	Mean Corpuscular Volume (MCV)	Day 3	89.4 fL	Standard Deviation 9.8
Placebo	Mean Corpuscular Volume (MCV)	Day 3	85.8 fL	Standard Deviation 6.2
Placebo	Mean Corpuscular Volume (MCV)	Day 0	86.8 fL	Standard Deviation 6
Placebo	Mean Corpuscular Volume (MCV)	Day 10	85.0 fL	Standard Deviation 1.9
Placebo	Mean Corpuscular Volume (MCV)	Day 7	85.2 fL	Standard Deviation 3.2
Placebo	Mean Corpuscular Volume (MCV)	Screening	86.9 fL	Standard Deviation 4.4

Secondary

Monocytes

Clinical lab evaluation of level of Monocytes in the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Monocytes	Day 3	5.4 % of Monocytes	Standard Deviation 2.9
HB-adMSCs	Monocytes	Day 7	5.4 % of Monocytes	Standard Deviation 3.1
HB-adMSCs	Monocytes	Day 10	5.2 % of Monocytes	Standard Deviation 3.6
HB-adMSCs	Monocytes	Screening	5.7 % of Monocytes	Standard Deviation 3.3
HB-adMSCs	Monocytes	Day 0	5.4 % of Monocytes	Standard Deviation 3.6
Placebo	Monocytes	Day 0	4.9 % of Monocytes	Standard Deviation 2.2
Placebo	Monocytes	Screening	5.4 % of Monocytes	Standard Deviation 2.7
Placebo	Monocytes	Day 7	5.5 % of Monocytes	Standard Deviation 4.8
Placebo	Monocytes	Day 3	5.8 % of Monocytes	Standard Deviation 4
Placebo	Monocytes	Day 10	6.5 % of Monocytes	Standard Deviation 3.8

Secondary

Myoglobin

Clinical lab evaluation of level of Myoglobin in the blood (ng/mL)

Time frame: Day 0, 3 7, and 10

Population: In the treatment arm, maximum number analyzed was 3 at Day 3 and in Placebo group maximum number analyzed was 1 at Day 3

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Myoglobin	Day 3	142.3 ng/mL	Standard Deviation 155.8
HB-adMSCs	Myoglobin	Day 7	21.5 ng/mL	Standard Deviation 0.7
HB-adMSCs	Myoglobin	Day 0	183.0 ng/mL	—
HB-adMSCs	Myoglobin	Day 10	50.3 ng/mL	Standard Deviation 48.2
Placebo	Myoglobin	Day 0	21.0 ng/mL	—
Placebo	Myoglobin	Day 3	100.0 ng/mL	—

Secondary

Neutrophils

Clinical lab evaluation of level of Neutrophils in the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Neutrophils	Day 0	79.4 % of Neutrophils	Standard Deviation 15.4
HB-adMSCs	Neutrophils	Day 7	73.5 % of Neutrophils	Standard Deviation 15.6
HB-adMSCs	Neutrophils	Day 3	77.0 % of Neutrophils	Standard Deviation 15.3
HB-adMSCs	Neutrophils	Day 10	75.1 % of Neutrophils	Standard Deviation 13.3
HB-adMSCs	Neutrophils	Screening	78.3 % of Neutrophils	Standard Deviation 14.6
Placebo	Neutrophils	Day 10	66.2 % of Neutrophils	Standard Deviation 17.2
Placebo	Neutrophils	Screening	75.8 % of Neutrophils	Standard Deviation 16.1
Placebo	Neutrophils	Day 0	80.7 % of Neutrophils	Standard Deviation 11.3
Placebo	Neutrophils	Day 3	75.3 % of Neutrophils	Standard Deviation 15.9
Placebo	Neutrophils	Day 7	75.7 % of Neutrophils	Standard Deviation 16.6

Secondary

NK Cell Surface Antigen (CD3-CD56+)

Clinical lab evaluation of Percentage of Cells CD3-CD56+ in the blood (%)

Time frame: Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 6 at Day 0 and in Placebo group maximum number analyzed was 1 at Day 0

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	NK Cell Surface Antigen (CD3-CD56+)	Day 0	66.4 % of Cells	Standard Deviation 58.5
HB-adMSCs	NK Cell Surface Antigen (CD3-CD56+)	Day 7	21.9 % of Cells	Standard Deviation 30.3
Placebo	NK Cell Surface Antigen (CD3-CD56+)	Day 0	6.9 % of Cells	—
Placebo	NK Cell Surface Antigen (CD3-CD56+)	Day 3	320.0 % of Cells	—

Secondary

Partial Thromboplastin Time (PTT)

Clinical lab evaluation of Partial Thromboplastin Time (PTT) (seconds)

Time frame: Screening, Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 25 at screening and in Placebo group maximum number analyzed was11 at screening. These were the largest N for which data for was collected for Partial Thromboplastin time

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Partial Thromboplastin Time (PTT)	Day 0	31.6 seconds	Standard Deviation 6.6
HB-adMSCs	Partial Thromboplastin Time (PTT)	Screening	32.0 seconds	Standard Deviation 5.5
HB-adMSCs	Partial Thromboplastin Time (PTT)	Day 3	32.2 seconds	Standard Deviation 5.8
HB-adMSCs	Partial Thromboplastin Time (PTT)	Day 7	31.0 seconds	Standard Deviation 6.9
HB-adMSCs	Partial Thromboplastin Time (PTT)	Day 10	24.5 seconds	Standard Deviation 12.7
Placebo	Partial Thromboplastin Time (PTT)	Day 0	29.8 seconds	Standard Deviation 4.2
Placebo	Partial Thromboplastin Time (PTT)	Day 3	26.5 seconds	Standard Deviation 6.4
Placebo	Partial Thromboplastin Time (PTT)	Screening	30.4 seconds	Standard Deviation 3.8
Placebo	Partial Thromboplastin Time (PTT)	Day 10	28.2 seconds	Standard Deviation 1.4

Secondary

Platelets

Clinical lab evaluation of level of Platelets in the blood (cells x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Platelets	Day 7	273.1 cells x 10^3/uL	Standard Deviation 119.6
HB-adMSCs	Platelets	Day 10	245.2 cells x 10^3/uL	Standard Deviation 110.5
HB-adMSCs	Platelets	Screening	232.4 cells x 10^3/uL	Standard Deviation 102.9
HB-adMSCs	Platelets	Day 0	237.5 cells x 10^3/uL	Standard Deviation 98.8
HB-adMSCs	Platelets	Day 3	258.2 cells x 10^3/uL	Standard Deviation 115.7
Placebo	Platelets	Day 3	295.8 cells x 10^3/uL	Standard Deviation 109
Placebo	Platelets	Day 0	304.8 cells x 10^3/uL	Standard Deviation 101.1
Placebo	Platelets	Day 10	303.8 cells x 10^3/uL	Standard Deviation 86.5
Placebo	Platelets	Day 7	323.1 cells x 10^3/uL	Standard Deviation 101.2
Placebo	Platelets	Screening	282.1 cells x 10^3/uL	Standard Deviation 122.8

Secondary

Potassium

Clinical lab evaluation of level of Potassium in the blood (mmol/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Potassium	Day 0	4.1 mmol/L	Standard Deviation 0.5
HB-adMSCs	Potassium	Day 7	4.3 mmol/L	Standard Deviation 1.3
HB-adMSCs	Potassium	Day 3	3.9 mmol/L	Standard Deviation 0.6
HB-adMSCs	Potassium	Day 10	4.5 mmol/L	Standard Deviation 1
HB-adMSCs	Potassium	Screening	4.2 mmol/L	Standard Deviation 0.5
Placebo	Potassium	Day 10	4.2 mmol/L	Standard Deviation 0.5
Placebo	Potassium	Screening	4.2 mmol/L	Standard Deviation 0.5
Placebo	Potassium	Day 0	4.1 mmol/L	Standard Deviation 0.6
Placebo	Potassium	Day 3	4.0 mmol/L	Standard Deviation 0.3
Placebo	Potassium	Day 7	4.5 mmol/L	Standard Deviation 0.5

Secondary

Protein Total

Clinical lab evaluation of total level of Protein in the blood (g/dL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Protein Total	Day 0	5.9 g/dL	Standard Deviation 0.7
HB-adMSCs	Protein Total	Day 7	5.6 g/dL	Standard Deviation 1.1
HB-adMSCs	Protein Total	Day 3	5.7 g/dL	Standard Deviation 0.8
HB-adMSCs	Protein Total	Day 10	6.0 g/dL	Standard Deviation 1.1
HB-adMSCs	Protein Total	Screening	6.2 g/dL	Standard Deviation 0.9
Placebo	Protein Total	Day 10	6.3 g/dL	Standard Deviation 0.4
Placebo	Protein Total	Screening	6.5 g/dL	Standard Deviation 0.8
Placebo	Protein Total	Day 0	6.0 g/dL	Standard Deviation 0.8
Placebo	Protein Total	Day 3	6.0 g/dL	Standard Deviation 0.7
Placebo	Protein Total	Day 7	6.1 g/dL	Standard Deviation 0.6

Secondary

Prothrombin Time (PT)

Clinical lab evaluation of Prothrombin Time (seconds)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Prothrombin Time (PT)	Screening	11.5 seconds	Standard Deviation 1.2
HB-adMSCs	Prothrombin Time (PT)	Day 3	14.4 seconds	Standard Deviation 3.1
HB-adMSCs	Prothrombin Time (PT)	Day 10	16.1 seconds	Standard Deviation 5.8
HB-adMSCs	Prothrombin Time (PT)	Day 7	15.3 seconds	Standard Deviation 4.1
HB-adMSCs	Prothrombin Time (PT)	Day 0	14.3 seconds	Standard Deviation 3.9
Placebo	Prothrombin Time (PT)	Day 10	14.3 seconds	Standard Deviation 1.7
Placebo	Prothrombin Time (PT)	Screening	12.0 seconds	Standard Deviation 1.4
Placebo	Prothrombin Time (PT)	Day 0	12.9 seconds	Standard Deviation 2
Placebo	Prothrombin Time (PT)	Day 3	13.9 seconds	Standard Deviation 2
Placebo	Prothrombin Time (PT)	Day 7	14.6 seconds	Standard Deviation 1.4

Secondary

Red Blood Cell (RBC) Count

Clinical lab evaluation of Red Blood Cell (RBC) Count in the blood (cells x 10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Red Blood Cell (RBC) Count	Day 0	4.2 cells x 10^3/uL	Standard Deviation 0.8
HB-adMSCs	Red Blood Cell (RBC) Count	Day 7	3.9 cells x 10^3/uL	Standard Deviation 0.8
HB-adMSCs	Red Blood Cell (RBC) Count	Day 3	4.1 cells x 10^3/uL	Standard Deviation 0.9
HB-adMSCs	Red Blood Cell (RBC) Count	Day 10	3.9 cells x 10^3/uL	Standard Deviation 0.9
HB-adMSCs	Red Blood Cell (RBC) Count	Screening	4.2 cells x 10^3/uL	Standard Deviation 0.7
Placebo	Red Blood Cell (RBC) Count	Day 10	4.3 cells x 10^3/uL	Standard Deviation 0.5
Placebo	Red Blood Cell (RBC) Count	Screening	4.5 cells x 10^3/uL	Standard Deviation 0.6
Placebo	Red Blood Cell (RBC) Count	Day 0	4.5 cells x 10^3/uL	Standard Deviation 1
Placebo	Red Blood Cell (RBC) Count	Day 3	4.5 cells x 10^3/uL	Standard Deviation 1
Placebo	Red Blood Cell (RBC) Count	Day 7	4.6 cells x 10^3/uL	Standard Deviation 0.8

Secondary

Red Cell Distribution Width (RDW)

Clinical lab evaluation of Red Cell Distribution Width (RDW) in the blood (%)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Red Cell Distribution Width (RDW)	Day 0	18.8 Red Cell Distribution Width %	Standard Deviation 23.5
HB-adMSCs	Red Cell Distribution Width (RDW)	Day 7	15.5 Red Cell Distribution Width %	Standard Deviation 4.5
HB-adMSCs	Red Cell Distribution Width (RDW)	Day 3	15.3 Red Cell Distribution Width %	Standard Deviation 4.8
HB-adMSCs	Red Cell Distribution Width (RDW)	Day 10	14.9 Red Cell Distribution Width %	Standard Deviation 2.1
HB-adMSCs	Red Cell Distribution Width (RDW)	Screening	14.4 Red Cell Distribution Width %	Standard Deviation 1.9
Placebo	Red Cell Distribution Width (RDW)	Day 10	14.3 Red Cell Distribution Width %	Standard Deviation 1.2
Placebo	Red Cell Distribution Width (RDW)	Screening	13.9 Red Cell Distribution Width %	Standard Deviation 1.4
Placebo	Red Cell Distribution Width (RDW)	Day 0	14.1 Red Cell Distribution Width %	Standard Deviation 1.5
Placebo	Red Cell Distribution Width (RDW)	Day 3	14.3 Red Cell Distribution Width %	Standard Deviation 2.1
Placebo	Red Cell Distribution Width (RDW)	Day 7	13.7 Red Cell Distribution Width %	Standard Deviation 0.9

Secondary

Serum Ferritin

Clinical lab evaluation of level of Serum Ferritin in the blood (ng/mL)

Time frame: Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 24 at Day 0 and in Placebo group maximum number analyzed was 7 at Day 0

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Serum Ferritin	Day 7	753.9 ng/mL	Standard Deviation 449.4
HB-adMSCs	Serum Ferritin	Day 10	509.0 ng/mL	Standard Deviation 384.9
HB-adMSCs	Serum Ferritin	Day 0	420.5 ng/mL	Standard Deviation 406
HB-adMSCs	Serum Ferritin	Day 3	499.6 ng/mL	Standard Deviation 424.2
Placebo	Serum Ferritin	Day 3	391.2 ng/mL	Standard Deviation 324
Placebo	Serum Ferritin	Day 7	361.0 ng/mL	Standard Deviation 397.8
Placebo	Serum Ferritin	Day 0	423.5 ng/mL	Standard Deviation 387.9
Placebo	Serum Ferritin	Day 10	63.2 ng/mL	—

Secondary

Sodium

Clinical lab evaluation of level of Sodium in the blood (mmol/L)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Sodium	Day 0	139.4 mmol/L	Standard Deviation 3.6
HB-adMSCs	Sodium	Day 7	132.3 mmol/L	Standard Deviation 29.6
HB-adMSCs	Sodium	Day 3	140.6 mmol/L	Standard Deviation 3.3
HB-adMSCs	Sodium	Day 10	139.2 mmol/L	Standard Deviation 4.4
HB-adMSCs	Sodium	Screening	137.8 mmol/L	Standard Deviation 3.5
Placebo	Sodium	Day 10	141.2 mmol/L	Standard Deviation 1.9
Placebo	Sodium	Screening	136.9 mmol/L	Standard Deviation 3.5
Placebo	Sodium	Day 0	137.9 mmol/L	Standard Deviation 3.5
Placebo	Sodium	Day 3	140.0 mmol/L	Standard Deviation 2.8
Placebo	Sodium	Day 7	139.3 mmol/L	Standard Deviation 3.2

Secondary

Troponin

Clinical lab evaluation of level of Troponin in the blood (ng/mL)

Time frame: Day 0, 3, 7, and 10

Population: In the treatment arm, maximum number analyzed was 14 at Day 0 and in Placebo group maximum number analyzed was 5 at Day 0

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	Troponin	Day 3	0.0 ng/mL	Standard Deviation 0
HB-adMSCs	Troponin	Day 0	0.5 ng/mL	Standard Deviation 1.8
HB-adMSCs	Troponin	Day 7	0.1 ng/mL	Standard Deviation 0.2
HB-adMSCs	Troponin	Day 10	0.0 ng/mL	Standard Deviation 0
Placebo	Troponin	Day 3	0.0 ng/mL	—
Placebo	Troponin	Day 0	0.0 ng/mL	Standard Deviation 0
Placebo	Troponin	Day 7	0.0 ng/mL	—

Secondary

White Blood Count (WBC)

Clinical lab evaluation of count of White Blood Cells (WBCs) in the blood (x10\^3/uL)

Time frame: Screening, Day 0, 3, 7, and 10

Arm	Measure	Group	Value (MEAN)	Dispersion
HB-adMSCs	White Blood Count (WBC)	Day 0	11.3 cells x 10^3/uL	Standard Deviation 10.5
HB-adMSCs	White Blood Count (WBC)	Day 7	12.1 cells x 10^3/uL	Standard Deviation 5.8
HB-adMSCs	White Blood Count (WBC)	Day 3	13.5 cells x 10^3/uL	Standard Deviation 11.3
HB-adMSCs	White Blood Count (WBC)	Day 10	10.4 cells x 10^3/uL	Standard Deviation 5
HB-adMSCs	White Blood Count (WBC)	Screening	8.4 cells x 10^3/uL	Standard Deviation 4
Placebo	White Blood Count (WBC)	Day 10	11.4 cells x 10^3/uL	Standard Deviation 5.8
Placebo	White Blood Count (WBC)	Screening	8.6 cells x 10^3/uL	Standard Deviation 5
Placebo	White Blood Count (WBC)	Day 0	10.3 cells x 10^3/uL	Standard Deviation 3.6
Placebo	White Blood Count (WBC)	Day 3	13.8 cells x 10^3/uL	Standard Deviation 8.7
Placebo	White Blood Count (WBC)	Day 7	12.7 cells x 10^3/uL	Standard Deviation 5.5

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

C-Reactive Protein (CRP)

Interleukin-10 (IL-10)

Interleukin-6 (IL-6)

Oxygenation

Return To Room Air (RTRA)

Tumor Necrosis Factor-Alpha (TNF-alpha)

7-Point Ordinal Scale

Absolute Basophils

Absolute Eosinophils

Absolute Immature Granulocytes

Absolute Lymphocytes

Absolute Monocytes

Absolute Neutrophils

Alanine Aminotransferase (SGPT)

Albumin

Albumin/Globulin (A/G) Ratio

Alkaline Phosphatase

Aspartate Aminotransferase (SGOT)

Basophils

Bilirubin Total

Blood Urea Nitrogen (BUN)

BUN/Creatinine Ratio

Calcium

Carbon Dioxide Total

CD4+/CD8+ Ratio

Chest X-Ray Score

Chloride

Computed Tomography (CT) Score

Creatinine Kinase MB (CK-MB)

D-dimer

Eosinophils

Estimated Glomerular Filtration Rate (eGFR) if African American

Estimated Glomerular Filtration Rate (eGFR) if Non-African American

Globulin Total

Glucose

Hematocrit

Hemoglobin

Immature Granulocytes

International Normalized Ratio (INR)

Lymphocytes

Mean Corpuscular Hemoglobin Concentration (MCHC)

Mean Corpuscular Hemoglobin (MCH)

Mean Corpuscular Volume (MCV)

Monocytes

Myoglobin

Neutrophils

NK Cell Surface Antigen (CD3-CD56+)

Partial Thromboplastin Time (PTT)

Platelets

Potassium

Protein Total

Prothrombin Time (PT)

Red Blood Cell (RBC) Count

Red Cell Distribution Width (RDW)

Serum Ferritin

Sodium